{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:40:50Z","timestamp":1792006850547,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Cancer Institute","award":["T32CA009206"],"award-info":[{"award-number":["T32CA009206"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL146402"],"award-info":[{"award-number":["R01HL146402"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1910285"],"award-info":[{"award-number":["W81XWH1910285"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA014520"],"award-info":[{"award-number":["P30CA014520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00259-022-05814-9","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T04:49:54Z","timestamp":1652330994000},"page":"3705-3716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["[68\u00a0Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity"],"prefix":"10.1007","volume":"49","author":[{"given":"Zachary T.","family":"Rosenkrans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F.","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Bernau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina A.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin J.","family":"Jeffery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefree J.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Valla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine M.","family":"Batterton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan B.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Sandbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Pirasteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-2179","authenticated-orcid":false,"given":"Reinier","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"5814_CR1","first-page":"48","volume":"5","author":"R Rafii","year":"2013","unstructured":"Rafii R, Juarez MM, Albertson TE, Chan AL. A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis. 2013;5:48\u201373.","journal-title":"J Thorac Dis"},{"key":"5814_CR2","doi-asserted-by":"publisher","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","volume":"3","author":"FJ Martinez","year":"2017","unstructured":"Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074. https:\/\/doi.org\/10.1038\/nrdp.2017.74.","journal-title":"Nat Rev Dis Primers"},{"key":"5814_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1183\/09031936.00185114","volume":"46","author":"J Hutchinson","year":"2015","unstructured":"Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46:795\u2013806. https:\/\/doi.org\/10.1183\/09031936.00185114.","journal-title":"Eur Respir J"},{"key":"5814_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1055\/s-2006-941449","volume":"23","author":"J Lorenz","year":"2006","unstructured":"Lorenz J, Blum M. Complications of percutaneous chest biopsy. Semin Intervent Radiol. 2006;23:188\u201393. https:\/\/doi.org\/10.1055\/s-2006-941449.","journal-title":"Semin Intervent Radiol"},{"key":"5814_CR5","doi-asserted-by":"publisher","unstructured":"Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB. In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States.2000 to 2011. Am J Respir Crit Care Med. 2016; 193:1161-1167https:\/\/doi.org\/10.1164\/rccm.201508-1632OC","DOI":"10.1164\/rccm.201508-1632OC"},{"key":"5814_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00017-5","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P, Ryerson CJ, Putman R, Oldham J, Salisbury M, Sverzellati N, et al. Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respir Med. 2021. https:\/\/doi.org\/10.1016\/S2213-2600(21)00017-5.","journal-title":"Lancet Respir Med"},{"key":"5814_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-pathol-012513-104706","volume":"9","author":"PJ Wolters","year":"2014","unstructured":"Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014;9:157\u201379. https:\/\/doi.org\/10.1146\/annurev-pathol-012513-104706.","journal-title":"Annu Rev Pathol"},{"key":"5814_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2353\/ajpath.2009.081170","volume":"175","author":"WD Hardie","year":"2009","unstructured":"Hardie WD, Glasser SW, Hagood JS. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol. 2009;175:3\u201316. https:\/\/doi.org\/10.2353\/ajpath.2009.081170.","journal-title":"Am J Pathol"},{"key":"5814_CR9","doi-asserted-by":"publisher","unstructured":"Acharya PS, Zukas A, Chandan V, Katzenstein A-LA, Pur\u00e9 E. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Human Pathology. 2006;37:352\u201360. https:\/\/doi.org\/10.1016\/j.humpath.2005.11.020.","DOI":"10.1016\/j.humpath.2005.11.020"},{"key":"5814_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39:783\u2013803. https:\/\/doi.org\/10.1007\/s10555-020-09909-3.","journal-title":"Cancer Metastasis Rev"},{"key":"5814_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","volume":"62","author":"A Altmann","year":"2021","unstructured":"Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62:160\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.244806.","journal-title":"J Nucl Med"},{"key":"5814_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.227967.","journal-title":"J Nucl Med"},{"key":"5814_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.119.233122","volume":"61","author":"T Watabe","year":"2020","unstructured":"Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models. J Nucl Med. 2020;61:563\u20139. https:\/\/doi.org\/10.2967\/jnumed.119.233122.","journal-title":"J Nucl Med"},{"key":"5814_CR14","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1007\/s00259-020-04859-y","volume":"47","author":"M Syed","year":"2020","unstructured":"Syed M, Flechsig P, Liermann J, Windisch P, Staudinger F, Akbaba S, et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging. 2020;47:2836\u201345. https:\/\/doi.org\/10.1007\/s00259-020-04859-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5814_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H","volume":"71","author":"J Niedermeyer","year":"1997","unstructured":"Niedermeyer J, Scanlan MJ, Garin-Chesa P, Daiber C, Fiebig HH, Old LJ, et al. Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer. 1997;71:383\u20139. https:\/\/doi.org\/10.1002\/(SICI)1097-0215(19970502)71:3%3c383::AID-IJC14%3e3.0.CO;2-H.","journal-title":"Int J Cancer"},{"key":"5814_CR16","doi-asserted-by":"publisher","unstructured":"Goldstein LA, Ghersi G, Pi\u00f1eiro-S\u00e1nchez ML, Monica S, Yeh Y, Flessate D, et al. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1997;1361:11\u20139. https:\/\/doi.org\/10.1016\/S0925-4439(97)00032-X.","DOI":"10.1016\/S0925-4439(97)00032-X"},{"key":"5814_CR17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2101852118","volume":"118","author":"J Millul","year":"2021","unstructured":"Millul J, Bassi G, Mock J, Elsayed A, Pellegrino C, Zana A, et al. An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. Proc Natl Acad Sci. 2021;118: e2101852118. https:\/\/doi.org\/10.1073\/pnas.2101852118.","journal-title":"Proc Natl Acad Sci"},{"key":"5814_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05475-0","author":"M Sollini","year":"2021","unstructured":"Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05475-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5814_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2967\/jnumed.119.241232","volume":"61","author":"J Calais","year":"2020","unstructured":"Calais J. FAP: the next billion dollar nuclear theranostics target? J Nucl Med. 2020;61:163\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.241232.","journal-title":"J Nucl Med"},{"key":"5814_CR20","doi-asserted-by":"publisher","first-page":"L174","DOI":"10.1152\/ajplung.00323.2020","volume":"321","author":"K Bernau","year":"2021","unstructured":"Bernau K, Leet JP, Bruhn EM, Tubbs AJ, Zhu T, Sandbo N. Expression of serum response factor in the lung mesenchyme is essential for development of pulmonary fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2021;321:L174\u201388. https:\/\/doi.org\/10.1152\/ajplung.00323.2020.","journal-title":"American Journal of Physiology-Lung Cellular and Molecular Physiology"},{"key":"5814_CR21","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s00018-020-03693-7","volume":"78","author":"THG Phan","year":"2021","unstructured":"Phan THG, Paliogiannis P, Nasrallah GK, Giordo R, Eid AH, Fois AG, et al. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cell Mol Life Sci. 2021;78:2031\u201357. https:\/\/doi.org\/10.1007\/s00018-020-03693-7.","journal-title":"Cell Mol Life Sci"},{"key":"5814_CR22","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","volume":"389","author":"L Richeldi","year":"2017","unstructured":"Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. The Lancet. 2017;389:1941\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(17)30866-8.","journal-title":"The Lancet"},{"key":"5814_CR23","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","volume":"61","author":"C Meyer","year":"2020","unstructured":"Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61:1171\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.236786.","journal-title":"J Nucl Med"},{"key":"5814_CR24","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, Lindner T, Burger E-M, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein\u2013targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60:1421\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.224469.","journal-title":"J Nucl Med"},{"key":"5814_CR25","doi-asserted-by":"publisher","unstructured":"R\u00f6hrich M, Naumann P, Giesel FL, Choyke P, Staudinger F, Wefers A, et al. Impact of 68Ga-FAPI-PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. Journal of Nuclear Medicine. 2020:jnumed.120.253062. https:\/\/doi.org\/10.2967\/jnumed.120.253062.","DOI":"10.2967\/jnumed.120.253062"},{"key":"5814_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12931-015-0206-6","volume":"16","author":"K Bernau","year":"2015","unstructured":"Bernau K, Ngam C, Torr EE, Acton B, Kach J, Dulin NO, et al. Megakaryoblastic leukemia-1 is required for the development of bleomycin-induced pulmonary fibrosis. Respir Res. 2015;16:45. https:\/\/doi.org\/10.1186\/s12931-015-0206-6.","journal-title":"Respir Res"},{"key":"5814_CR27","doi-asserted-by":"publisher","unstructured":"Bernau K, Skibba M, Leet JP, Furey S, Gehl C, Li Y, et al. Selective inhibition of bromodomain-containing protein 4 reduces myofibroblast transdifferentiation and pulmonary fibrosis. Front Mol Med. 2022;2. https:\/\/doi.org\/10.3389\/fmmed.2022.842558.","DOI":"10.3389\/fmmed.2022.842558"},{"key":"5814_CR28","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1183\/09031936.00182412","volume":"42","author":"CJ Scotton","year":"2013","unstructured":"Scotton CJ, Hayes B, Alexander R, Datta A, Forty EJ, Mercer PF, et al. Ex vivo micro-computed tomography analysis of bleomycin-induced lung fibrosis for preclinical drug evaluation. Eur Respir J. 2013;42:1633. https:\/\/doi.org\/10.1183\/09031936.00182412.","journal-title":"Eur Respir J"},{"key":"5814_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jcp.41.4.467","volume":"41","author":"T Ashcroft","year":"1988","unstructured":"Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:467\u201370. https:\/\/doi.org\/10.1136\/jcp.41.4.467.","journal-title":"J Clin Pathol"},{"key":"5814_CR30","first-page":"3","volume":"19","author":"RT Dorr","year":"1992","unstructured":"Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol. 1992;19:3\u20138.","journal-title":"Semin Oncol"},{"key":"5814_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2967\/jnumed.114.147421","volume":"56","author":"B Bondue","year":"2015","unstructured":"Bondue B, Sherer F, Van Simaeys G, Doumont G, Egrise D, Yakoub Y, et al. PET\/CT with 18F-FDG\u2013 and 18F-FBEM\u2013labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. J Nucl Med. 2015;56:127\u201332. https:\/\/doi.org\/10.2967\/jnumed.114.147421.","journal-title":"J Nucl Med"},{"key":"5814_CR32","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811\u201323. https:\/\/doi.org\/10.1056\/NEJMra1705751.","journal-title":"N Engl J Med"},{"key":"5814_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/resp.13223","volume":"23","author":"LT Vaszar","year":"2018","unstructured":"Vaszar LT, Larsen BT, Swanson KL, Ryu JH, Tazelaar HD. Diagnostic utility of surgical lung biopsies in elderly patients with indeterminate interstitial lung disease. Respirology. 2018;23:507\u201311. https:\/\/doi.org\/10.1111\/resp.13223.","journal-title":"Respirology"},{"key":"5814_CR34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/thoraxjnl-2017-210177","volume":"73","author":"T Hewson","year":"2018","unstructured":"Hewson T, McKeever TM, Gibson JE, Navaratnam V, Hubbard RB, Hutchinson JP. Timing of onset of symptoms in people with idiopathic pulmonary fibrosis. Thorax. 2018;73:683\u20135. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-210177.","journal-title":"Thorax"},{"key":"5814_CR35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042320-030240","author":"BJ Moss","year":"2021","unstructured":"Moss BJ, Ryter SW, Rosas IO. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu Rev Pathol. 2021. https:\/\/doi.org\/10.1146\/annurev-pathol-042320-030240.","journal-title":"Annu Rev Pathol"},{"key":"5814_CR36","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1164\/rccm.201212-2297OC","volume":"188","author":"C Hung","year":"2013","unstructured":"Hung C, Linn G, Chow Y-H, Kobayashi A, Mittelsteadt K, Altemeier WA, et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med. 2013;188:820\u201330. https:\/\/doi.org\/10.1164\/rccm.201212-2297OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"5814_CR37","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1172\/JCI71386","volume":"124","author":"MW Parker","year":"2014","unstructured":"Parker MW, Rossi D, Peterson M, Smith K, Sikstr\u00f6m K, White ES, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Investig. 2014;124:1622\u201335. https:\/\/doi.org\/10.1172\/JCI71386.","journal-title":"J Clin Investig"},{"key":"5814_CR38","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00432-013-1471-8","volume":"139","author":"Y Liao","year":"2013","unstructured":"Liao Y, Ni Y, He R, Liu W, Du J. Clinical implications of fibroblast activation protein-\u03b1 in non-small cell lung cancer after curative resection: a new predictor for prognosis. J Cancer Res Clin Oncol. 2013;139:1523\u20138. https:\/\/doi.org\/10.1007\/s00432-013-1471-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5814_CR39","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2967\/jnumed.119.226993","volume":"60","author":"Z Varasteh","year":"2019","unstructured":"Varasteh Z, Mohanta S, Robu S, Braeuer M, Li Y, Omidvari N, et al. Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04. J Nucl Med. 2019;60:1743\u20139. https:\/\/doi.org\/10.2967\/jnumed.119.226993.","journal-title":"J Nucl Med"},{"key":"5814_CR40","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2174\/156652412803833607","volume":"12","author":"M Jacob","year":"2012","unstructured":"Jacob M, Chang L, Pur\u00e9 E. Fibroblast activation protein in remodeling tissues. Curr Mol Med. 2012;12:1220\u201343. https:\/\/doi.org\/10.2174\/156652412803833607.","journal-title":"Curr Mol Med"},{"key":"5814_CR41","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s10529-015-1855-8","volume":"37","author":"L Wenlong","year":"2015","unstructured":"Wenlong L, Leilei Y, Wei F, Yi C, Jing T, Lanzhi M, et al. Luciferase expression is driven by the promoter of fibroblast activation protein-\u03b1 in murine pulmonary fibrosis. Biotech Lett. 2015;37:1757\u201363. https:\/\/doi.org\/10.1007\/s10529-015-1855-8.","journal-title":"Biotech Lett"},{"key":"5814_CR42","doi-asserted-by":"publisher","first-page":"8070","DOI":"10.1074\/jbc.M115.701433","volume":"291","author":"M-H Fan","year":"2016","unstructured":"Fan M-H, Zhu Q, Li H-H, Ra H-J, Majumdar S, Gulick DL, et al. Fibroblast activation protein (FAP) accelerates collagen degradation and clearance from lungs in mice*. J Biol Chem. 2016;291:8070\u201389. https:\/\/doi.org\/10.1074\/jbc.M115.701433.","journal-title":"J Biol Chem"},{"key":"5814_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejphar.2017.05.022","volume":"809","author":"C Egger","year":"2017","unstructured":"Egger C, Cannet C, G\u00e9rard C, Suply T, Ksiazek I, Jarman E, et al. Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. Eur J Pharmacol. 2017;809:64\u201372. https:\/\/doi.org\/10.1016\/j.ejphar.2017.05.022.","journal-title":"Eur J Pharmacol"},{"key":"5814_CR44","doi-asserted-by":"publisher","unstructured":"R\u00f6hrich M, Leitz D, Glatting FM, Wefers AK, Weinheimer O, Flechsig P, et al. Fibroblast activation protein specific PET\/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study. Journal of Nuclear Medicine. 2021:jnumed.121.261925. https:\/\/doi.org\/10.2967\/jnumed.121.261925.","DOI":"10.2967\/jnumed.121.261925"},{"key":"5814_CR45","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","volume":"3","author":"C Bergmann","year":"2021","unstructured":"Bergmann C, Distler JHW, Treutlein C, Tascilar K, M\u00fcller A-T, Atzinger A, et al. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. The Lancet Rheumatology. 2021;3:e185\u201394. https:\/\/doi.org\/10.1016\/S2665-9913(20)30421-5.","journal-title":"The Lancet Rheumatology"},{"key":"5814_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2613.2002.00220.x","volume":"83","author":"G Izbicki","year":"2002","unstructured":"Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83:111\u20139. https:\/\/doi.org\/10.1046\/j.1365-2613.2002.00220.x.","journal-title":"Int J Exp Pathol"},{"key":"5814_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/01902148.2014.979516","volume":"41","author":"JD Williamson","year":"2015","unstructured":"Williamson JD, Sadofsky LR, Hart SP. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis. Exp Lung Res. 2015;41:57\u201373. https:\/\/doi.org\/10.3109\/01902148.2014.979516.","journal-title":"Exp Lung Res"},{"key":"5814_CR48","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.2174\/1381612043383539","volume":"10","author":"CP Bleeker-Rovers","year":"2004","unstructured":"Bleeker-Rovers CP, Boerman OC, Rennen HJ, Corstens FH, Oyen WJ. Radiolabeled compounds in diagnosis of infectious and inflammatory disease. Curr Pharm Des. 2004;10:2935\u201350. https:\/\/doi.org\/10.2174\/1381612043383539.","journal-title":"Curr Pharm Des"},{"key":"5814_CR49","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1164\/rccm.200505-717OC","volume":"173","author":"NI Chaudhary","year":"2006","unstructured":"Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173:769\u201376. https:\/\/doi.org\/10.1164\/rccm.200505-717OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"5814_CR50","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.biocel.2007.08.011","volume":"40","author":"A Moeller","year":"2008","unstructured":"Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40:362\u201382. https:\/\/doi.org\/10.1016\/j.biocel.2007.08.011.","journal-title":"Int J Biochem Cell Biol"},{"key":"5814_CR51","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1165\/rcmb.2009-0345OC","volume":"43","author":"BS Shea","year":"2010","unstructured":"Shea BS, Brooks SF, Fontaine BA, Chun J, Luster AD, Tager AM. Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol. 2010;43:662\u201373. https:\/\/doi.org\/10.1165\/rcmb.2009-0345OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"5814_CR52","doi-asserted-by":"publisher","unstructured":"D\u00e9sog\u00e8re P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, et al. Type I collagen\u2013targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Science Translational Medicine. 2017;9:eaaf4696. https:\/\/doi.org\/10.1126\/scitranslmed.aaf4696.","DOI":"10.1126\/scitranslmed.aaf4696"},{"key":"5814_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000088062","volume":"73","author":"HH Meissner","year":"2006","unstructured":"Meissner HH, Soo Hoo GW, Khonsary SA, Mandelkern M, Brown CV, Santiago SM. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration. 2006;73:197\u2013202. https:\/\/doi.org\/10.1159\/000088062.","journal-title":"Respiration"},{"key":"5814_CR54","doi-asserted-by":"publisher","first-page":"19755","DOI":"10.1038\/srep19755","volume":"6","author":"NP Withana","year":"2016","unstructured":"Withana NP, Ma X, McGuire HM, Verdoes M, van der Linden WA, Ofori LO, et al. Non-invasive imaging of idiopathic pulmonary fibrosis using cathepsin protease probes. Sci Rep. 2016;6:19755. https:\/\/doi.org\/10.1038\/srep19755.","journal-title":"Sci Rep"},{"key":"5814_CR55","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1038\/s41467-019-11863-w","volume":"10","author":"RH Kimura","year":"2019","unstructured":"Kimura RH, Wang L, Shen B, Huo L, Tummers W, Filipp FV, et al. Evaluation of integrin \u03b1v\u03b26 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis. Nat Commun. 2019;10:4673. https:\/\/doi.org\/10.1038\/s41467-019-11863-w.","journal-title":"Nat Commun"},{"key":"5814_CR56","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1164\/rccm.202004-1132OC","volume":"203","author":"SL Brody","year":"2021","unstructured":"Brody SL, Gunsten SP, Luehmann HP, Sultan DH, Hoelscher M, Heo GS, et al. Chemokine receptor 2\u2013targeted molecular imaging in pulmonary fibrosis. Am J Respir Crit Care Med. 2021;203:78\u201389. https:\/\/doi.org\/10.1164\/rccm.202004-1132OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"5814_CR57","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.2967\/jnumed.117.193532","volume":"58","author":"P D\u00e9sog\u00e8re","year":"2017","unstructured":"D\u00e9sog\u00e8re P, Tapias LF, Rietz TA, Rotile N, Blasi F, Day H, et al. Optimization of a collagen-targeted pet probe for molecular imaging of pulmonary fibrosis. J Nucl Med. 2017;58:1991\u20136. https:\/\/doi.org\/10.2967\/jnumed.117.193532.","journal-title":"J Nucl Med"},{"key":"5814_CR58","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1021\/jacs.8b12342","volume":"141","author":"J Wahsner","year":"2019","unstructured":"Wahsner J, D\u00e9sog\u00e8re P, Abston E, Graham-O\u2019Regan KA, Wang J, Rotile NJ, et al. (68)Ga-NODAGA-indole: an allysine-reactive positron emission tomography probe for molecular imaging of pulmonary fibrogenesis. J Am Chem Soc. 2019;141:5593\u20136. https:\/\/doi.org\/10.1021\/jacs.8b12342.","journal-title":"J Am Chem Soc"},{"key":"5814_CR59","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1039\/c9sc04821a","volume":"11","author":"EA Akam","year":"2020","unstructured":"Akam EA, Abston E, Rotile NJ, Slattery HR, Zhou IY, Lanuti M, et al. Improving the reactivity of hydrazine-bearing MRI probes for in vivo imaging of lung fibrogenesis. Chem Sci. 2020;11:224\u201331. https:\/\/doi.org\/10.1039\/c9sc04821a.","journal-title":"Chem Sci"},{"key":"5814_CR60","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00259-017-3917-8","volume":"45","author":"T Win","year":"2018","unstructured":"Win T, Screaton NJ, Porter JC, Ganeshan B, Maher TM, Fraioli F, et al. Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF). Eur J Nucl Med Mol Imaging. 2018;45:806\u201315. https:\/\/doi.org\/10.1007\/s00259-017-3917-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5814_CR61","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028\u201340. https:\/\/doi.org\/10.1038\/nm.2807.","journal-title":"Nat Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05814-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05814-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05814-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T03:13:16Z","timestamp":1661224396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05814-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["5814"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05814-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"14 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were conducted under protocols approved by the Institutional Animal Care and Use Committee at the University of Wisconsin-Madison.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A. P. receives departmental research support from GE Healthcare. A. P. serves as a consultant for TheraCea and Sanofi Genzyme. M. M., F. V., and C. R. D. are all current (F. V.) or former employees (M. M., C. R. D.) at SOFIE. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}